This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In “MT in anticoagulated patients: Direct oral anticoagulants versus vitamin K antagonists,” L'Allinec et al. compared procedural and clinical outcomes of mechanical thrombectomy (MT) in 115 patients on direct oral anticoagulants (DOACs) and 106 patients on vitamin K antagonists (VKAs) and found that reperfusion (modified Thrombolysis in Cerebral Infarction score [mTICI] 2b/3 or mTICI 2c/3), 90-day mortality, and excellent 90-day outcome (modified Rankin Scale [mRS] 0–1 or equal to prestroke mRS) were better in patients on DOACs. Frontera cautioned that this study does not clearly indicate that clot retrieval is easier in patients on DOACs because (1) up to 50% of VKA users may have had a subtherapeutic international normalized ratio (INR) (28% of patients had INR <2% and 24% did not have INR) and (2) data on the MT devices are not provided. Further study is warranted comparing patients on individual DOACs with patients on VKAs with therapeutic INRs who are treated with the latest MT techniques. However, these findings add to existing literature on the benefit of DOACs vs VKAs about the risk of ischemic and hemorrhagic events.
In “MT in anticoagulated patients: Direct oral anticoagulants versus vitamin K antagonists,” L'Allinec et al. compared procedural and clinical outcomes of mechanical thrombectomy (MT) in 115 patients on direct oral anticoagulants (DOACs) and 106 patients on vitamin K antagonists (VKAs) and found that reperfusion (modified Thrombolysis in Cerebral Infarction score [mTICI] 2b/3 or mTICI 2c/3), 90-day mortality, and excellent 90-day outcome (modified Rankin Scale [mRS] 0–1 or equal to prestroke mRS) were better in patients on DOACs. Frontera cautioned that this study does not clearly indicate that clot retrieval is easier in patients on DOACs because (1) up to 50% of VKA users may have had a subtherapeutic international normalized ratio (INR) (28% of patients had INR <2% and 24% did not have INR) and (2) data on the MT devices are not provided. Further study is warranted comparing patients on individual DOACs with patients on VKAs with therapeutic INRs who are treated with the latest MT techniques. However, these findings add to existing literature on the benefit of DOACs vs VKAs about the risk of ischemic and hemorrhagic events.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.